The Center for Infectious Disease Research (CIDR) and PreCyte, Inc. have been awarded three specialized grants in support of the Indicator Cell Assay Platform (iCAP).


$5.3 million in three specialized grants has been awarded in support of the Indicator Cell Assay Platform (iCAP) developed by PreCyte, Inc. in collaboration with the Center for Infectious Disease Research (CIDR).

The indicator cell assay platform (iCAP) is analogous to the early pregnancy test in which, without knowing what to look for, the patient’s blood or urine was injected into a rabbit and readout was the response of the rabbit’s ovaries to the sample. In the iCAP, patient serum is applied to specifically selected standardized indicator cells and the response of the cells provides the readout. The indicator cell assay exploits cells’ natural capability to amplify and integrate multi-analyte signals. The assay has been demonstrated to be 94% accurate for the detection of ALS in a murine model, and in preliminary studies the assay had 69% sensitivity and 91% specificity classifying early-stage Alzheimer’s disease from normal samples.

Read the $2M SBIR Phase II Funding Award for the for the Application of the Indicator Cell Assay Platform (iCAP) for the Classification of Indeterminate Pulmonary Nodules (LINK)

Read the $300k SBIR Phase I Funding Award for the Application of the Indicator Cell Assay Platform (iCAP) to the selection of candidate drugs for Alzheimer’s disease (LINK)

Read the $3M SBIR Phase IIB Funding Award for the Further Optimization and Evaluation of the Indicator Cell Assay Platform (iCAP) for the Early Detection of Alzheimer's Disease (LINK)